Page last updated: 2024-08-16

thalidomide and daunorubicin

thalidomide has been researched along with daunorubicin in 7 studies

Research

Studies (7)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	3 (42.86)	29.6817
2010's	3 (42.86)	24.3611
2020's	1 (14.29)	2.80

Authors

Authors	Studies
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A	1
Barbieri, KP; Carlos, IZ; Chelucci, RC; Chung, MC; de Faria Fernandes Belone, A; de Melo, TR; Diório, SM; do Nascimento, DC; dos Santos, JL; Placeres, MC; Rosa, PS; Yamasaki, PR	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M	1
Estey, EH; Thall, PF	1
Albitar, M; Andreeff, M; Cortes, J; Estey, E; Faderl, S; Garcia-Manero, G; Giles, F; Kantarjian, H; Keating, M; Koller, C; O'Brien, S; Thomas, D	1
Barge, R; Bertsch, U; Blau, I; Bos, GM; Breitkreutz, I; Breitkreuz, I; Croockewit, S; de Weerdt, O; Delforge, M; Duersen, U; Goldschmidt, H; Joosten, P; Lokhorst, HM; Martin, H; Naumann, R; Salwender, HJ; Schaafsma, R; Scheid, C; Schlenzka, J; Schmidt-Wolf, I; Sinnige, H; Sonneveld, P; van der Holt, B; van Marwijk-Kooy, M; van Oers, MH; Vellenga, E; Verhoef, G; Wijermans, P; Wittebol, S; Zweegman, S	1

Reviews

1 review(s) available for thalidomide and daunorubicin

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016

Trials

2 trial(s) available for thalidomide and daunorubicin

Article	Year
A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome. Cancer, 2003, Mar-01, Volume: 97, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Endothelial Growth Factors; Humans; Intercellular Signaling Peptides and Proteins; Leukemia, Myeloid, Acute; Liposomes; Lymphokines; Middle Aged; Myelodysplastic Syndromes; Neovascularization, Pathologic; Prognosis; Survival Analysis; Thalidomide; Topotecan; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors	2003
Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma. Haematologica, 2008, Volume: 93, Issue:1 Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Dexamethasone; Female; Humans; Male; Medical Oncology; Middle Aged; Multiple Myeloma; Remission Induction; Thalidomide; Thioguanine; Treatment Outcome; Vincristine	2008

Article

Year

A randomized trial of liposomal daunorubicin and cytarabine versus liposomal daunorubicin and topotecan with or without thalidomide as initial therapy for patients with poor prognosis acute myelogenous leukemia or myelodysplastic syndrome.

Cancer, 2003, Mar-01, Volume: 97, Issue:5

Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Endothelial Growth Factors; Humans; Intercellular Signaling Peptides and Proteins; Leukemia, Myeloid, Acute; Liposomes; Lymphokines; Middle Aged; Myelodysplastic Syndromes; Neovascularization, Pathologic; Prognosis; Survival Analysis; Thalidomide; Topotecan; Treatment Outcome; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors

2003

Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma.

Haematologica, 2008, Volume: 93, Issue:1

Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Dexamethasone; Female; Humans; Male; Medical Oncology; Middle Aged; Multiple Myeloma; Remission Induction; Thalidomide; Thioguanine; Treatment Outcome; Vincristine

2008

Other Studies

4 other study(ies) available for thalidomide and daunorubicin

Article	Year
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chemical research in toxicology, 2010, Volume: 23, Issue:1 Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship	2010
Synthesis and evaluation of novel dapsone-thalidomide hybrids for the treatment of type 2 leprosy reactions. Bioorganic & medicinal chemistry letters, 2014, Jul-15, Volume: 24, Issue:14 Topics: Animals; Anti-Bacterial Agents; Cell Line; Dapsone; Dose-Response Relationship, Drug; Humans; Leprosy; Mice; Mice, Nude; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium leprae; Structure-Activity Relationship; Thalidomide	2014
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology. Disease models & mechanisms, 2023, 03-01, Volume: 16, Issue:3 Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries	2023
New designs for phase 2 clinical trials. Blood, 2003, Jul-15, Volume: 102, Issue:2 Topics: Acute Disease; Adenine Nucleotides; Adult; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Bayes Theorem; Bias; Biomarkers; Clinical Trials, Phase II as Topic; Clofarabine; Confounding Factors, Epidemiologic; Cytarabine; Daunorubicin; Drug Carriers; False Negative Reactions; Follow-Up Studies; Humans; Idarubicin; Leukemia, Myeloid; Liposomes; Middle Aged; Patient Selection; Randomized Controlled Trials as Topic; Remission Induction; Research Design; Thalidomide; Topotecan; Treatment Outcome	2003